The deal involves Bruker’ ClinProt platform. Greg Rice of HealthLinx and Gongyi Shi of Bruker Daltonics’ Fremont, California, lab discovered the biomarkers as a result of the two companies’ ongoing collaboration. Both will be recognised as co-inventors.
Under the new agreement, Bruker Daltonics and HealthLinx will file a joint PCT patent application and share costs associated with the patent and development of the biomarkers. The patent will focus on the use of the biomarkers as a diagnostic test for the detection of “Complications of Pregnancy”. It is envisaged that the test will be a blood test performed at the first antenatal visit and/or subsequently during pregnancy. The test will seek to diagnose women with a predisposition to a number of complications in pregnancy: pre-eclampsia, pre-term labour, miscarriage and gestational diabetes. Women will be classified as either having a high risk or a low risk of developing complications of pregnancy, allowing the gynecologist and/or general practitioner to undertake more appropriate management and/or intervention strategies during the pregnancy to improve outcomes for both mother and baby.d9A2t49mkex